Participants 39 128 4
the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors
Participants 351 455 4
patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs).
Participants 606 656 3
patients with progressive disease on a lower dose.
Participants 657 918 5
Two open-label, controlled, multicenter, intergroup, international, randomized phase III studies were submitted -- one conducted by the European Organization for Research and Treatment of Cancer (n = 946) and the other by the Southwest Oncology Group (n = 746).
